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Control of CXCR2 activity through its
ubiquitination on K327 residue
Héloise M Leclair1,2,3, Sonia M Dubois1,2,3, Sandy Azzi1,2,3, Julie Dwyer1,2,3, Nicolas Bidère1,2,3 and Julie Gavard1,2,3,4*
Abstract
Background: The interleukin-8 chemokine (IL-8) G-protein coupled receptor CXCR2 governs pro-inflammatory and
pro-angiogenic responses in leukocytes and endothelial cells. At a molecular standpoint, CXCR2 is widely reported to
operate through calcium flux, phosphoinoisitide 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK). While
CXCR2 trafficking is suspected to be intertwined with its signaling, the exact mechanism is not fully elucidated.
Results: Here, we identified the lysine 327 within the CXCR2 C-terminal tail as a key residue for ubiquitination,
internalization, and signaling. First, the substitution to an arginine of K327 mutation was associated with a reduction in
CXCR2 poly-ubiquitination. While WT CXCR2 was rapidly internalized following IL-8 administration, K327R mutant
remained at the plasma membrane. Finally, K327R mutant failed to promote the recruitment of β-arrestin2, as
estimated by imagery and bioluminescence resonance transfer. As a consequence, the activation of intracellular
signaling, including both early events such as ERK phosphorylation and the increase in calcium flux, and the latter
activation of the AP1 and NF-κB transcription factors, was blunted.
Conclusions: Overall, our results demonstrate that CXCR2 ubiquitination on K327 residue modulates agonist-activated
CXCR2 cell sorting and intracellular signaling. Thus, the inhibition of K327 ubiquitination might emerge as an effective
mean to curb exacerbated CXCR2 signaling in several pathological conditions, such as inflammatory diseases and
cancer.
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Background
CXCR2 is a seven transmembrane G-protein coupled re-
ceptor (GPCR) for the ELR + CXCL8 (IL-8) chemokine
that transduces pro-angiogenic and pro-inflammatory
responses in endothelial and immune cells [1-5]. Indeed,
IL-8/CXCR2 signaling axis plays multiple functions in the
course of physiological and pathological neo-vessel forma-
tion. Likewise, IL-8 signaling is instrumental in leukocyte
migration [6]. Notably, it does so by stimulating endothe-
lial cell proliferation, permeability, and migration, and by
attracting lymphocytes, macrophages, and neutrophils to
perivascular regions. For instance, we recently demon-
strated that IL-8 operates through CXCR2 and phosphoi-
nositide 3-kinase γ (PI3Kγ) to promote angiogenesis and
macrophage accumulation in retina, while curbing the
endothelial barrier function [3]. Importantly, interfering
with this pathway quelled laser-induced vascular dysfunc-
tions in mouse retina. Similar observations were done in
the context of cancers, including malignant brain tumors,
prostate tumors, pancreatic ductal adenocarcinoma, che-
mically induced-skin tumors, Ras-mediated tumors and
inflammation-driven tumors [2,7-10]. These data place
CXCR2 as a promising pharmacological target in many
human diseases and pathological conditions [4]. In that
view, targeting GPCR constitutes the primary option for
pharmacological intervention and drug development [11].
However, many of these compounds act as direct antago-
nists leaving uncertain their ability to target pathways that
are aberrantly and/or constitutively active.
Physiologically, GPCR signaling can be either twisted or
interrupted by intracellular cascades implying endocytosis
and ubiquitination [12]. Similarly to the CXCL12 (also
known as stromal derived factor 1α, SDF1α) chemokine
receptor CXCR4, ligand-activated CXCR2 undergoes
endocytosis in clathrin-coated vesicles [13,14]. In that
view, the viral CXCR2 homolog vGPCR from the Kaposi
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Sarcoma Herpes Virus, harbors a consensus adaptin 2
(AP2) binding motif in its C-terminal tail, which drives its
constitutive shuttling in clathrin-coated vesicles, and fur-
ther adjusts its signaling activity [15]. Moreover, CXCR2
internalization might involve scaffold proteins, including
β-arrestins, AP2, actin-binding proteins and yet to be de-
termined PDZ ligand motif binding proteins [13,14,16-19].
However, how exactly CXCR2 signaling, intracellular
sorting and ubiquitination are coordinated is not fully elu-
cidated. This prompted us to explore the molecular contri-
bution of lysine residues, operating as ubiquitin acceptors,
to CXCR2 activity.
Results and discussion
The ligation of G-protein coupled receptor CXCR2
drives its relocation into endosomal compartments,
where it could be targeted for lysosomal degradation
[13]. This dynamic process has been shown to rely on
specific motifs, including lysine residues within the
C-terminal domain [13]. To investigate which lysine
could contribute to the fine-tuning of CXCR2 traffic-
king, we first proceed to amino-acid sequence alignment
between residues 316 and 347 on the human sequence.
Our in silico analysis identified two lysine residues on
position 327 and 337 in the human sequence, conserved
in pig, mouse, and chicken, and shared between CXCR2
and CXCR1 (Figure 1a). As expected, structural predic-
tion did not reveal major changes in the overall CXCR2
molecular organization in the context of K-R mutations
(Figure 1b). Point mutation in each of these two lysines
was thus engineered on the full-length (FL) receptor,
harboring an AU5 tag. The expression of K327R (named
R1) and K337R (named R2) FL CXCR2 mutants was
found similar to the one of wild type (WT) when trans-
fected in HEK-293T cells (Figure 1c). These constructs
have been thus used throughout the study. Because ly-
sine residues functions as ubiquitin-acceptors, we next
setup the experimental conditions to visualize CXCR2
ubiquitination, using validated methods for intracellular
targets [20,21]. CXCR2 immunoprecipitated fractions
were analyzed under denaturing conditions, ie 1% SDS
final concentration to prevent non-covalent protein in-
teractions but without heat denaturation that could favor
membrane protein aggregation. Using these conditions,
the monoclonal anti-ubiquitin antibody (clone P4D1)
readily detected modified CXCR2 in the high molecular-
weight fraction (Figure 1d). Additionally, denaturation
prior immunoprecipitation dissociated putative con-
taminations with associated ubiquitinated partners of
CXCR2, such as β-arrestins (Figure 1d). Similarly, ubi-
quitination addition was detected in the CXCR2 im-
munoprecipitated fractions from endothelial cells that
endogenously expressed the receptor (Additional file 1:
Figure S1). As a further control, CXCR2 antagonist
SB225002 [3,22] was sufficient to curtail CXCR2 ubiqui-
tination in response to IL-8 (Figure 1e). Of note, CXCR2
ubiquitination species accumulated in cells pretreated
with the proteasome inhibitor MG132, suggesting that
ubiquitination marks CXCR2 for degradation (Figure 1f ).
We next examine the ubiquitination profile of K-R
CXCR2 mutants. Interestingly, the typical ubiquitination
ladder discerned in response to IL-8 challenge in WT
CXCR2-expressing HEK-293T cells was profoundly re-
duced when K327 residue was substituted for an
arginine (Figure 1g). Our data thus suggest that the
K327 residue is critical for K-linked ubiquitination of ac-
tivated CXCR2.
We next aimed at understanding how K327 could
modulate CXCR2 trafficking. In this scenario, localization
of K-R CXCR2 mutants was further characterized by con-
focal microscopy (Figure 2). In starved non-stimulated
HEK-293T cells, WT CXCR2 primarily labeled plasma
membrane and redistributed in internal vesicle-like dots
shortly following IL-8 challenge (15 minutes, Figure 2a).
By contrast, K327R CXCR2 remained accumulated at the
plasma membrane regardless of IL-8 treatment. On the
other hand, the K337R mutant mimicked WT CXCR2, as
it shuttled from the plasma membrane to internal vesicles
(Figure 2a). This was found similar to endogenous CXCR2
dynamics in IL-8-challenged THP1 monocytes (Additional
file 2: Figure S2). Likewise, CXCR2 internalization, as
monitored through antibody uptake assay followed by an
acid wash, was enhanced in response to IL-8 administra-
tion, unless K327 was mutated (Figure 2b). Co-labeling
with Rab7 and AP2, which illuminates late and early endo-
somes, respectively, indeed supports the notion that WT
and K337R CXCR2 were endocytosed upon IL-8 stimula-
tion (Figure 2c). Conversely, plasma membrane staining of
the K327R mutant was not curbed by IL-8 treatment, un-
like WT and K337R mutant (Figure 2c). Altogether, our
results show that the K327R point mutation is sufficient
to restrain CXCR2 internalization upon ligand binding,
suggesting therefore that this residue is critical to ensure
proper trafficking of the activated receptor.
We next investigated whether K327 residue participates
to CXCR2 signaling ability. To this aim, one of the most
proximal events in GPCR activation, namely β-arrestin2
activation was first assessed. Interestingly, K327R single
substitution prevented from IL-8-induced β-arrestin2
clustering, observed normally in cells transfected with
WT and K337R CXCR2 (Figure 3a-b). Likewise, K327R
CXCR2 mutant less efficiently activated β-arrestin2 in re-
sponse to IL-8, as estimated through Bioluminescence
Resonance Energy Transfer (BRET) technology (Figure 3c).
As phosphorylation is also an important hallmark of
GPCR activation upon ligation [23], we checked the status
of CXCR2 tyrosine phosphorylation in immunoprecipita-
tion experiments (Figure 4a). As expected, IL-8 drove WT
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CXCR2 phosphorylation. In sharp contrast, the signal
was barely detectable when K327R mutant was ecto-
pically expressed in HEK-293T (Figure 4a). Secondly,
intracellular signaling, namely extracellular regulated
kinase 1/2 (ERK1/2) phosphorylation and increase in
calcium influx, was evaluated in WT, K327R and K337R
CXCR2 expressing HEK-293T cells (Figure 4b-c). Our
data showed that IL-8 could not elicit either CXCR2
and ERK1/2 phosphorylation, or the elevation in intra-
cellular calcium concentration in K327R CXCR2-
transfected cells. Furthermore, luciferase-based reporter
assays unveiled that K327 mutation abrogates AP1 and
NF-κB activation downstream of CXCR2 stimulation by
IL-8 (Figure 4d). Thus, our data demonstrate that the
signaling function of CXCR2 is compromised when the
K327 residue is not available for ubiquitination.
Figure 1 K327 residue is critical for IL8-induced CXCR2 ubiquitination. a. Partial sequence alignment between Homo sapiens (h), Mus
musculus, Gallus gallus, and Sus scrofa CXCR2 (ILRB), and between hCXCR2 and hCXCR1 (ILRA). Conserved residues are in black, not conserved
one are in grey. Conserved lysines are highlighted in red. b. CXCR2 secondary structure was predicted using LOMETS software and modeled
using Swiss-PDB viewer. K327 and K337 are indicated with an arrow and colored in red. c-g. HEK-293T cells were transfected with pCEFL-AU5
plasmid (mock), in frame wild type (WT), K327R (R1), and K337R (R2) mutant forms of FL CXCR2. c. Anti-AU5 and anti-Tubulin western-blots were
performed 24 h later. d. CXCR2 immunoprecipitation (IP) was performed onto SDS denaturated protein lysates from IL-8-treated samples (15 min,
50 ng/ml), and further analyzed by western-blots for CXCR2, β-arrestin and CXCR2. Input for CXCR2 is also presented. e-f. Alternatively, cells were
pre-incubated with CXCR2 antagonist (SB225002, 50 μM, 1 hour) or MG132 proteasome inhibitor (25 μM, 45 min). g. CXCR2 IP and WB were
performed as in (d) in starved cells (-) and in IL-8-challenged cells (+, 15 min, 50 ng/ml). Pixel intensities of the ubiquitination lanes were quantified
using Image J software and normalized to untreated mock lane. Means + sem are shown. Each panel is representative of three independent
experiments. *p < 0.05.
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Conclusions
We report here that the conserved K327 residue on
CXCR2 is a key ubiquitin acceptor upon IL-8 challenge
in ectopic cell models. Of note, interfering with this
post-translational modification abrogates CXCR2 traf-
ficking and signaling. In this scenario, CXCR2 poly-
ubiquitination, by a yet to be determined ligase, precedes
β-arrestin2 recruitment and CXCR2 internalization, and
is therefore placed upstream in the IL-8-mediated intra-
cellular signaling cascade. Our data thus highlight an
original option to specifically and finely tune CXCR2 sig-
naling in pathological situations, where aberrantly ele-
vated, such as tumor angiogenesis and inflammation.
Methods
Cell culture and transfections
HEK-293T cells (ATCC) were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum and antibiotics. Previously described pro-
tocols for transfection were used [24].
Figure 2 K327 residue drives CXCR2 trafficking in response to IL-8. HEK-293T cells were transfected with pCEFL-AU5 plasmid (mock), containing
in frame wild type (WT), K327R (R1), and K337R (R2) mutant forms of FL CXCR2. a. CXCR2 staining was analyzed by confocal microscopy in 1 h-starved
cells (control) followed by IL-8 stimulation (50 ng/ml, 15 min). b. CXCR2 antibody uptake was performed as described in methods and analyzed by
confocal microscopy in control and IL-8 stimulated cells. Internalization was estimated by the percentage of cells with CXCR2 vesicular staining per
transfected cells. Results are expressed as the mean ± sem, n = 150 cells. c. Alternatively, IL-8-challenged cells were co-transfected with either Rab7-GFP
or AP2-GFP 24 h prior confocal analysis. Pearson’s correlation coefficient (P. coef) was calculated on 5 and 3 samples for Rab7-GFP and AP2-GFP,
respectively. Each panel is representative of three independent experiments. Scale bars: 10 μm. **p < 0.01, ***p < 0.001.
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Reagents and antibodies
Recombinant human interleukin 8 (IL-8) was purchased
from Peprotech, CXCR2 antagonist SB225002 and
MG132 were from Calbiochem. The following antibodies
were used: mouse and rabbit anti-CXCR2, rabbit anti-
ERK2, mouse anti-tubulin, mouse anti-poly-ubiquitinated
chains, clone P4D1 (Santa Cruz); rabbit anti-phopho-
ERK1/2, rabbit anti-β-arrestin1/2 (Cell Signaling); mouse
anti-phospho-tyr (4G10 clone, Millipore), and mouse anti-
AU5 (Eurogentec). AlexaFluor-conjugated antibodies were
from Invitrogen.
DNA constructs
Full length (FL) K327R (R1) and K337R (R2) CXCR2
mutants were prepared from human wild type (WT)
CXCR2, cloned in frame in pCEFL-AU5 expression vec-
tor [15]. pGFP-β-arrestin2 [24], EGFP-β2-adaptin (AP2)
[25] and pYFP-Rab7 were described previously [26].
Structural analysis
CXCR2 protein sequence was introduced to the LOMETS
software [27] and the predicted secondary structure with
the lowest Z-score was chosen for modeling, using the
Swiss-PDB viewer 36 (www.expasy.org/spdbv/). Mutations
were introduced using the mutation tool, according to the
manufacturer’s instruction.
Immunofluorescence
HEK-293T cells were grown onto glass coverslips, fixed
(PBS-paraformaldheyde 4%), permeabilized (PBS-Triton
0.5%) and blocked (PBS-BSA 3%). Following incubations
with primary and AlexaFluor-conjugated secondary anti-
bodies for 1 h in PBS-BSA 1.5%, samples were mounted
(ProLong, Invitrogen), visualized and analyzed under
confocal microscopy (TCS/SP5, Leica). Pearson’s coeffi-
cient was measured using the Image J plugin on 3 to 5
samples.
Ubiquitination assays
HEK-293T cells were transfected with mock, CXCR2-WT
or K327R (R1) cDNA plasmids. 24 hours post-transfection,
cells were treated as indicated and were further lysed
(25 mM Hepes pH7.4, 130 mM NaCl, 10% glycerol, 8 mM
β − glycerophosphate, 0.2% Igepal, 1 mM DTT, 1 mM
NaVO4, 1 mM NaF, protease inhibitors, 1% SDS and 1 μl
benzonase (250 U/μl, Novagen)) on ice. After 30 minutes,
SDS was diluted to reach a final concentration of 0.1% and
samples were precleared with Protein G agarose (Sigma)
for 30 min and then incubated with antibody to CXCR2
Figure 3 K327R mutation eliminates β-arrestin2 recruitment. HEK-293T cells were transfected with pCEFL-AU5 plasmid (mock), containing in
frame wild type (WT), K327R (R1), and K337R (R2) mutant forms of FL CXCR2. One day later, cells were starved (control) or exposed to IL-8 (50 ng/ml,
15 min). a-b. Cells were additionally transfected with β-arrestin2-GFP (βarr2) and the percentage of cells with clustered β-arrestin2-GFP staining was
evaluated. Results are expressed as the mean ± sem, n = 150 cells. c. BRET analysis was performed as described in methods, ΔmBRET was calculated
and the mean ± sem is shown. Each panel is representative of three independent experiments. Scale bars: 10 μm. **p < 0.01, ***p < 0.001.
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and Protein G agarose for 1 hour at 4°C. Ubiquitination
status were analyzed by immunoblot using antibody
against ubiquitin.
Western-blots
Protein lysates were processed for western-blots as de-
scribed previously [2]. Equal amounts of protein were
loaded onto 4-12% acrylamide gradient gels (NUPAGE,
Invitrogen) and transferred onto PVDF membranes
(Thermo Scientific) for further analysis using the infra-
red scanner system (LiCOR).
Cytosolic calcium measurements
Changes in intracellular Ca2+ levels were assessed in
HEK-293T as previously described [28], using Fluo-4
NW calcium indicators (Life Technologies), following
the manufacturer’s instructions. Fluorescence was read
in 96-well plate format at room temperature, using ap-
propriate settings (excitation/emission 494/516 nm,
BMG microplate reader).
Luciferase assays
Firefly luciferase constructs downstream of NF-κB and
AP1 consensus sites [2] were co-transfected with Renilla
luciferase pRL-TK plasmid (Promega), together with
250 ng pCEFL-AU5-CXCR2 constructs. Following incu-
bation with IL-8 (50 ng/ml, 6 hours), luciferase activity
was analyzed as described previously [2].
BRET assays
HEK-293T cells were transfected with 0.1 μg per well
of the DNA construct coding for double-brilliance
Figure 4 K327R mutation abrogates CXCR2 signaling in response to IL-8. HEK-293T cells were transfected with pCEFL-AU5 plasmid (mock),
containing in frame wild type (WT), K327R (R1), and K337R (R2) mutant forms of FL CXCR2. One day later, cells were starved (control) or exposed to IL-8
(50 ng/ml, 15 min, unless specified). a. Anti-phospho-Tyr (4G10), anti-CXCR2 western-blots were performed in CXCR2 immunoprecipitated (IP) fraction.
b. Calcium flux was measured using the Fluo4NW probe in response to IL-8 for the indicated times. Fluorescent units were normalized to control
conditions. c. Anti-AU5, anti-pERK1/2 and anti-ERK2 western-blots were performed. Pixel intensities of the pERK1/2 lanes were quantified using Image J
software and normalized to total ERK2. d. Promoter activity of both NF-κB and AP1 was monitored through luciferase-based assays. Each panel is
representative of three independent experiments. Means + sem are shown. **p < 0.01, ***p < 0.001.
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β-arrestin2 [29], together with CXCR2 constructs. Two-
days after transfection, IL-8 (50 ng/ml) and DeepBlue
coelenterazine substrate (5 μM, Perkin Elmer) were ad-
ded. Luminescence was measured (Mithras fluorescence-
luminescence detector, Berthold) as previously described
in [29]. The BRET signal was determined by calculating
the ratio of the light emitted by the fluorescent acceptor
and the light emitted by Luc. The values (ΔmBRET) were
corrected by subtracting the background BRET signals
detected in non-stimulated cells.
Statistical analysis
All data are expressed as mean + s.e.m from three inde-
pendent experiments. One-way and two-way ANOVA
tests with post hoc Tukey’s analysis were used to assess
statistical significance (Prism 6.0 GraphPad Software), and
P values are indicated on figures as follows: * for p < 0.05,
** for p < 0.01, and *** for p < 0.001.
Additional files
Additional file 1: Human endothelial cells were serum-starved
16 h (-) prior IL-8 challenge (+, 100 ng/ml, 15 min). CXCR2
immunoprecipitation (IP) was performed as described in methods
and IP fractions were blotted against CXCR2 and ubiquitination (Ub).
Additional file 2: Human THP1 monocytes were serum-starved
16 h (control) prior IL-8 challenge (+, 50 ng/ml, 15 min). CXCR2
(Santa Cruz) and AP2 (Becton Dickinson) staining were analyzed by
confocal microscopy. Scale bar: 10 μm.
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